Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in foveolar cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15424
Sealed predictions
- SYTL5 in dopamine neurons, braak-0.44 (p 0.237) → +0.67 (p 0.048)receipt 15431
Swarm cases
receipt 15431: SYTL5 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.351, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.148, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.36 (p 0.137, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.35, sign flips 0; without severely affected donors +0.23 (p 0.351, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SYTL5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts